Dren Bio is a privately held, biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have significant expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathologic cells, protein aggregates and other disease-causing agents. At Dren we selectively engage an effector cell for targeted depletion of diseased cells or agents. Our pipeline is currently comprised of two distinct drug discovery programs.
DR-01, the Company’s lead product candidate from its enhanced antibody-dependent cellular cytotoxicity (“ADCC”) program, induces the potent antibody-mediated killing of a cell type that possesses intrinsic cytotoxic potential and is responsible for a multitude of hematologic malignancies. In addition to the opportunity in liquid cancers, DR-01 will be evaluated in auto-immune indications driven by the cytotoxic immune cells. DR-01 aims to address unmet need in indications with no approved therapies, with the first IND filing planned for early 2022.
Dren’s second program, its Targeted Myeloid Engager and Phagocytosis Platform, is a proprietary bispecific antibody-based technology that provides for a novel mechanism of action that encompasses (i) direct engagement of myeloid and cancer cells, (ii) stimulation of myeloid cells to release key cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment, (iii) phagocytosis and killing of tumor cells and (iv) cross-presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory. Targeted activation of antigen presenting cells has the potential to elicit a sustained, durable response with an attractive safety profile.